These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 27003784)

  • 1. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
    Oueslati A
    J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
    Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
    J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
    Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
    Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
    Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
    PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
    Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the presence of doubly phosphorylated α-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases.
    Fayyad M; Erskine D; Majbour NK; Vaikath NN; Ghanem SS; Sudhakaran IP; Abdesselem H; Lamprokostopoulou A; Vekrellis K; Morris CM; Attems J; El-Agnaf OMA
    Brain Pathol; 2020 Jul; 30(4):831-843. PubMed ID: 32324926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
    Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
    Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
    Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
    PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
    Wales P; Pinho R; Lázaro DF; Outeiro TF
    J Parkinsons Dis; 2013; 3(4):415-59. PubMed ID: 24270242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
    Oueslati A; Fournier M; Lashuel HA
    Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.
    Wu J; Lou H; Alerte TN; Stachowski EK; Chen J; Singleton AB; Hamilton RL; Perez RG
    Neuroscience; 2012 Apr; 207():288-97. PubMed ID: 22326202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.
    Landeck N; Hall H; Ardah MT; Majbour NK; El-Agnaf OM; Halliday G; Kirik D
    Mol Neurodegener; 2016 Aug; 11(1):61. PubMed ID: 27549140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
    Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
    Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
    Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease.
    Tenreiro S; Reimão-Pinto MM; Antas P; Rino J; Wawrzycka D; Macedo D; Rosado-Ramos R; Amen T; Waiss M; Magalhães F; Gomes A; Santos CN; Kaganovich D; Outeiro TF
    PLoS Genet; 2014 May; 10(5):e1004302. PubMed ID: 24810576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated NUB1 distinguishes α-synuclein in Lewy bodies from that in glial cytoplasmic inclusions in multiple system atrophy.
    Tanji K; Miki Y; Mori F; Kon T; Kakita A; Takahashi H; Wakabayashi K
    Brain Pathol; 2019 Nov; 29(6):803-812. PubMed ID: 31006160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.
    Peelaerts W; Bousset L; Van der Perren A; Moskalyuk A; Pulizzi R; Giugliano M; Van den Haute C; Melki R; Baekelandt V
    Nature; 2015 Jun; 522(7556):340-4. PubMed ID: 26061766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.